Saxenda vs Wegovy: clearing up the confusion before you choose

The misconception worth correcting first: they're not the same drug with a different label

A common assumption is that Saxenda and Wegovy are essentially interchangeable — two branded versions of the same active ingredient. They're not. Saxenda contains liraglutide, a GLP-1 receptor agonist given as a daily injection. Wegovy contains semaglutide at 2.4mg (or, since April 2026, up to 7.2mg), given once weekly. Both target GLP-1 receptors, but semaglutide has a longer half-life, which is why once-weekly dosing is possible. The practical differences flow from there: one injection a day versus one a week, different titration schedules, different peak results in trials, and different side-effect profiles in terms of timing and intensity.

Saxenda's starting dose is 0.6mg daily, rising over five weeks to the 3mg maintenance dose. Wegovy's pathway starts at 0.25mg weekly and titrates over roughly 16–20 weeks to 2.4mg, or, for eligible patients, further to 7.2mg following the MHRA's April 2026 approval of the dedicated single-dose pen. The titration period for Wegovy is longer, which many patients find helps with tolerability. For a broader look at how semaglutide compares across different products, the semaglutide vs Wegovy page sets out the full picture.

Both medicines are licensed for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. That eligibility overlap can make the choice feel arbitrary, it isn't, and the distinction becomes clearer when you look at the evidence.

What the clinical trial data actually shows about weight loss

Trial results are not marketing materials, but they do provide a useful reference point. In the SCALE Obesity and Prediabetes trial (56 weeks), Saxenda produced an average weight reduction of around 8% in participants without diabetes, compared with roughly 2.6% for placebo. Wegovy's pivotal STEP 1 trial (68 weeks) reported an average reduction of approximately 15% at the 2.4mg maintenance dose, as published in the New England Journal of Medicine. The higher 7.2mg Wegovy dose, approved by the MHRA in early 2026, reported around 20.7% average loss over 72 weeks in trials, approaching the results seen with tirzepatide.

These are population averages across different trial designs and durations, so direct comparison carries caveats. What the data does suggest is that, on average, once-weekly semaglutide produces greater weight loss than daily liraglutide. That picture is consistent with how NICE appraised Wegovy (TA875), recommending it as a clinically meaningful treatment within specialist weight management services.

Individual responses vary. Some people do well on Saxenda; others find the daily injection difficult to sustain or experience side effects that make it unsuitable. A prescriber assesses your history, your current medicines, and your lifestyle before recommending either.

Side effects, storage and day-to-day differences that matter

The side-effect profile of both medicines is dominated by gastrointestinal symptoms: nausea, loose stools, constipation, indigestion, and reduced appetite. These tend to be most noticeable when starting or after a dose increase, and settle for many people within the first couple of weeks at each level. Because Saxenda is taken every day, some patients notice a more constant low-level background of these effects rather than a predictable post-injection window.

With Wegovy's once-weekly schedule, many people identify the day or two after their injection as the time when nausea is most likely, and adjust their routine accordingly. Keeping the pen in the fridge door (somewhere visible as a reminder) and picking a consistent day of the week helps with adherence. Both medicines require refrigeration; always check the Patient Information Leaflet for the permitted room-temperature storage window before travel, rather than relying on memory.

The MHRA's Yellow Card scheme is the mechanism for reporting unexpected side effects for either medicine. Pancreatitis is a known, infrequent but serious risk for GLP-1 medicines generally, severe stomach pain radiating to the back needs prompt medical assessment. Your prescriber will discuss the full risk profile with you, and aftercare support is available at nume seven days a week.

For a deeper comparison of Wegovy alongside other GLP-1 options, the GLP-1 treatment comparison page covers the broader landscape.

What this means for choosing between the two, and where a prescriber fits in

Saxenda is no longer the default recommendation for most adults seeking weight management treatment. The trial evidence, and the direction of UK clinical guidance, points toward once-weekly semaglutide delivering greater average weight reduction with a dosing schedule most people find easier to sustain. That said, Wegovy is not suitable for everyone, and for some patients Saxenda may still be the right clinical choice, or neither medicine may be appropriate, and tirzepatide (Mounjaro) may be worth considering instead. You can read about how Wegovy sits within the wider set of weight-loss treatments available through nume before starting a consultation.

One practical point: nume currently dispenses Wegovy but not Saxenda. If Saxenda is specifically what you're exploring, the Saxenda vs Wegovy comparison page has more detail on Saxenda's clinical profile in its own right. For questions about Wegovy's position relative to other prescription options, the full Wegovy comparison hub covers each in turn.

Which medicine suits you is a clinical decision, made with a prescriber who knows your full picture. Our prescribers are available through a free consultation (reviewed the same working day) and the clinical team is on hand for aftercare seven days a week. If cost is part of your thinking, the Wegovy cost page sets out what private treatment typically involves.